
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc., a leader in regenerative medicine, has demonstrated significant potential with its expansive portfolio of advanced wound care and sports medicine products. The company operates in an underpenetrated market, highlighting opportunities for growth, especially with additional total addressable markets beyond wound care. As the company progresses through FY25, normalized operating dynamics are anticipated to lead to improved financial performance in the latter half of the fiscal year.
Bears say
Organogenesis Holdings Inc is facing significant downside risks concerning its PuraPly product growth, with potential impacts stemming from Medicare Part B pricing for amniotic products and regulatory hurdles that competitors may navigate more efficiently. The company's financial outlook has been further exacerbated by delays associated with the ReNu program, which incurred approximately $30 million in expenditures during FY24 and has postponed potential market clearance by several months. Additionally, challenges related to the uptake of new products and adverse clinical data outcomes contribute to a negative sentiment surrounding the company's capabilities to capture market share effectively.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares